---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-023188"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T15:24:42.920945+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Virpax regains Nasdaq compliance; court approves settlement with Sorrento/Scilex

## Summary
- Nasdaq notified Virpax that closing bid price was at $1.00 or greater for 10 consecutive business days through March 14, 2024; compliance regained.
- Bankruptcy Court for Southern District of Texas entered order approving settlement between Virpax, Sorrento Therapeutics, and Scilex Pharmaceuticals on March 14, 2024.
- Settlement Agreement and Mutual Release incorporated by reference from prior 8-K; no financial terms disclosed in this filing.

## SEC filing metadata
- accession: 0001213900-24-023188
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000121390024023188/0001213900-24-023188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000121390024023188/ea0201947-8k_virpaxphrm.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-023188
- JSON: https://secwatch.observer/filing/0001213900-24-023188.json
- Plain text: https://secwatch.observer/filing/0001213900-24-023188.txt

## Key facts
- Listing & Compliance Notices
  Virpax Pharmaceuticals, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 15, 2024, Virpax Pharmaceuticals, Inc. (the “Company”), received a letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that for the last 10 consecutive business days, from March 1, through 14, 2024, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390024023188/0001213900-24-023188-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.